Fycompa perampanel: Interim extension study data

Interim data from the open-label Phase III Study 307 extension study in 1,218 patients who completed 1 of the double-blind Phase III Study 304, 305 or 306 trials showed that once-daily perampanel had an acceptable tolerability profile at a median treatment duration of 51.4 weeks, with serious adverse events reported in 13.2% of patients. Eisai also said that reduced seizure frequency and improved responder rates from the double-blind portions were maintained during 1-2 years of continued perampanel treatment. Overall median reductions in seizure frequency in patients included in each 13-week interval of perampanel treatment were 39.2% for weeks 14-26 (n=1,114), 46.5% for weeks 40-52 (n=731) and 58.1% for weeks 92-104 (n=59). Overall responder rates were 41.4% for weeks 14-26, 46.9% for weeks 40-52 and 62.7% for weeks 92-104. Data were published in Epilepsia. ...